DNA-based Cancer Vaccine Development Solutions

Nucleic acid immunization utilizes the host's cellular machinery to express antigens, offering a stable and versatile platform for cancer immunotherapy. Unlike viral vectors, DNA vaccines are non-live, non-spreading, and non-pathogenic.

Creative Biolabs leverages decades of expertise to provide a comprehensiveDNA-based cancer vaccine development solution . Our services encompass novel plasmid design, chimeric antigen engineering, and advanced delivery optimization (Electroporation), specifically tailored to overcome the low immunogenicity often associated with naked DNA.

Get a Quote

Overcoming Barriers in DNA Vaccine Potency

While DNA vaccines offer superior safety and stability profiles, their translation into effective cancer therapies faces significant hurdles that our platform addresses:

▶ Cellular Uptake Efficiency: Naked DNA (pDNA) has poor transfection efficiency in vivo. We solve this via optimized Electroporation (EP) protocols.
▶ Breaking Immune Tolerance: Self-antigens in tumors are weakly immunogenic. Our Chimeric DNA Design incorporates xenogeneic domains to bypass tolerance.
▶ Antigen Presentation: To ensure robust CD4+/CD8+ T cell priming, we employ VaxBody™ technology to target professional APCs directly.
▶ Immunostimulation: We co-deliver molecular adjuvants (e.g., IL-12, IL-15) encoded within the plasmid to create a potent inflammatory microenvironment.

Consult Our Experts

Our Solutions

We provide a full spectrum of preclinical development services, focusing on enhancing the "Design-Delivery-Immunity" axis:

Precision Vector Construction

Proprietary plasmid backbones optimized for high-level expression in mammalian cells, utilizing CMV/CAG promoters and Kozak sequences.

Advanced Adjuvant Integration

Development of genetic adjuvants (cytokines IL-12, IL-33, chemokines) co-formulated or co-expressed to boost adaptive immunity.

Target-Specific Solutions

Specialized vaccine strategies for Melanoma, Colon, Prostate, Cervical, and Breast cancers, including p62 protein targeting.

Electroporation Delivery

Standardized in vivo electroporation protocols for Intramuscular (IM) or Intradermal (ID) administration to maximize DNA uptake.

Comprehensive DNA Vaccine Services

Creative Biolabs offers specialized modules designed to address specific immunogenicity and manufacturing challenges in the preclinical phase:

VaxBody™ - Antibody-Encoded DNA Platform

VaxBody™ is an innovative DNA vaccine strategy where the plasmid encodes a modified human antibody. By engineering the CDR and Fc regions, the expressed protein can simultaneously bind to APCs with high affinity and stimulate dual CD4+/CD8+ T cell responses, significantly enhancing antigen presentation compared to standard antigens.

Learn More →

Chimeric DNA Vaccine Design

To overcome tolerance to self-antigens, we design hybrid plasmids coding for chimeric proteins containing both xenogeneic (foreign) and homologous (self) oncoantigen domains. This strategy effectively circumvents immune tolerance while maintaining specificity for the tumor target.

Learn More →

DNA Delivery Optimization (Electroporation)

We provide optimized protocols for in vivo electroporation (EP), which has been proven to increase DNA uptake by magnitude orders. Our service includes parameter optimization for electrical pulses to balance expression levels with tissue safety in preclinical models.

Learn More →

Anti-cancer DNA Vaccine Encoding p62

Targeting the autophagy protein p62, which is required for tumorigenesis and progression. We develop and evaluate DNA vaccines capable of encoding p62 to inhibit GATA-4-associated senescence, offering a novel therapeutic pathway for solid tumors.

Learn More →

Genetic Adjuvant Optimization

We design "cocktail" DNA vaccines that co-express cytokines (e.g., IL-12, IL-15, IL-33). These molecular adjuvants are critical for polarizing Th1 responses and enhancing the quantity and quality of the anti-tumor immune response.

Learn More →

Streamlined Development Workflow

Our integrated process moves from computational design to preclinical proof-of-concept with speed and precision:

Step 1: Antigen Design & Codon Optimization

Service: Comprehensive selection of high-affinity tumor neoantigens or TAAs using AI-driven bioinformatics. Our codon optimization strategy adjusts GC content, eliminates cryptic splice sites, and optimizes mRNA secondary structure to maximize translation efficiency in human cells.

Step 2: Vector Engineering

Service: Engineering of high-performance plasmid backbones incorporating tissue-specific promoters and CpG motifs for innate immune activation. We specialize in multicistronic vector design to co-express antigens with molecular adjuvants (e.g., IL-12) for synergistic effects.

Step 3: Plasmid Production & Quality Control

Service: High-yield plasmid production using endotoxin-free purification technologies. Our rigorous Quality Control ensures >95% supercoiled fraction and minimal host cell DNA/RNA/protein contamination, providing consistent material for downstream studies.

Step 4: Delivery Optimization (In Vitro)

Service: Validation of antigen expression and proper folding in mammalian cells via Western Blot and Immunofluorescence. We also assess antigen processing and presentation efficiency on MHC molecules to predict immunogenicity.

Step 5: Preclinical Immunogenicity Study

Service: In vivo assessment using optimized electroporation parameters. We perform detailed immune profiling, including Tetramer staining for specific CD8+ T cells, ELISpot for IFN-γ secretion, and tumor challenge studies to evaluate therapeutic efficacy.

Note: This workflow is strictly for preclinical research and development purposes.

Start Your Project

Advanced Technology Platforms

Our DNA vaccine solutions are supported by proprietary technologies ensuring high expression and potent immunogenicity:

Proprietary mammalian expression vectors featuring optimized regulatory elements (CMV/CAG promoters, Intron A, WPRE) to drive robust and sustained antigen expression. We also offer antibiotic-free (AF) plasmid backbones to enhance safety profiles.

Strong promoters (CMV, CAG) and enhancers
Intron A insertion for enhanced mRNA stability
Antibiotic-free selection markers available

A unique platform transforming antigens into antibody-like structures. By engineering antigens into the CDR loops and utilizing an optimized Fc region, VaxBody™ actively targets Antigen Presenting Cells (APCs) via Fc receptors, significantly boosting cross-presentation.

Simultaneous stimulation of CD4+ and CD8+ T cells
Enhanced binding to Fc receptors on APCs
Optimized CDR regions for stability

Advanced EP delivery systems that generate controlled electric fields to permeabilize cell membranes transiently. This technology increases DNA uptake by orders of magnitude compared to naked DNA injection, enabling dose-sparing and potent immune priming.

Customizable pulse parameters
Intramuscular (IM) and Intradermal (ID) applicators
Significant reduction in required DNA dose

State-of-the-art immunomonitoring capabilities, including multicolor Flow Cytometry, ELISpot, and multiplex cytokine assays. We provide deep insights into T-cell phenotype, function, and memory generation.

IFN-γ ELISpot for T cell frequency
Intracellular Cytokine Staining (ICS) for functionality
Tetramer staining for antigen specificity

High-Expression Vectors

VaxBody™ Engineering

In Vivo Electroporation

Immune Profiling

Inquire About Our Technology

Why Choose Creative Biolabs

Innovative Design Strategies

Pioneers in Chimeric DNA and VaxBody™ technologies to overcome tolerance issues.

Superior Delivery

Integrated Electroporation protocols ensuring maximum antigen expression.

Comprehensive Targets

Proven track record in developing vaccines for Melanoma, Prostate, and Breast cancers.

Flexibility

Services ranging from single plasmid construction to complete preclinical efficacy studies.

Request a Free Consultation

Frequently Asked Questions

Q: How do DNA vaccines compare to mRNA or protein-based vaccines?

A: DNA vaccines are significantly more stable and easier to manufacture than mRNA or proteins. They are particularly effective at inducing CD8+ T cell responses (cytotoxic T cells) because the antigen is produced intracellularly and presented via MHC Class I molecules.

Q: What is the primary advantage of the VaxBody™ platform?

A: VaxBody™ encodes antigens in the form of an antibody structure. This design allows the expressed protein to bind directly to Fc receptors on dendritic cells (DCs), significantly enhancing antigen uptake and presentation compared to standard soluble antigens.

Q: Why is electroporation (EP) recommended for DNA delivery?

A: Naked plasmid DNA has low transfection efficiency when injected alone. EP uses brief electrical pulses to create temporary pores in cell membranes, increasing DNA uptake by 100-1000 fold, which correlates directly with stronger immune responses.

Q: Can you design DNA vaccines that break immune tolerance?

A: Yes. We use Chimeric DNA strategies, incorporating xenogeneic (non-human) domains into the antigen sequence. These foreign elements help the immune system recognize the self-antigen as a threat, effectively circumventing tolerance mechanisms.

Q: What is the typical turnaround time for a custom DNA vaccine project?

A: Timelines vary by scope. Constructing and verifying a custom plasmid typically takes 2-4 weeks. A full preclinical immunogenicity study (including mouse immunization and readout) generally requires an additional 8-12 weeks.

Ask Our Experts

Related Resources